Read by QxMD icon Read

British Journal of Cancer

David S Shulman, Kelly Klega, Alma Imamovic-Tuco, Andrea Clapp, Anwesha Nag, Aaron R Thorner, Eliezer Van Allen, Gavin Ha, Stephen L Lessnick, Richard Gorlick, Katherine A Janeway, Patrick J Leavey, Leo Mascarenhas, Wendy B London, Kieuhoa T Vo, Kimberly Stegmaier, David Hall, Mark D Krailo, Donald A Barkauskas, Steven G DuBois, Brian D Crompton
The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced.In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40...
March 18, 2019: British Journal of Cancer
Ben C Creelan, Jhanelle E Gray, Tawee Tanvetyanon, Alberto A Chiappori, Takeshi Yoshida, Michael J Schell, Scott J Antonia, Eric B Haura
BACKGROUND: Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patients with resistant EGFR-mutant lung cancer. METHODS: An open-label, dose-escalation phase 1/2 trial (NCT01999985) with 2-stage expansion was conducted with 25 lung cancer patients. Dose expansion required activating EGFR mutations and progression following prior EGFR TKI...
March 18, 2019: British Journal of Cancer
Emma R Still, Mariia O Yuneva
This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License.
March 14, 2019: British Journal of Cancer
Tsuyoshi Hamada, Chen Yuan, Matthew B Yurgelun, Kimberly Perez, Natalia Khalaf, Vicente Morales-Oyarvide, Ana Babic, Jonathan A Nowak, Douglas A Rubinson, Marios Giannakis, Kimmie Ng, Peter Kraft, Meir J Stampfer, Edward L Giovannucci, Charles S Fuchs, Shuji Ogino, Brian M Wolpin
BACKGROUND: Individuals with a family history of cancer may be at increased risk of pancreatic cancer. Ashkenazi Jewish (AJ) individuals carry increased risk for pancreatic cancer and other cancer types. METHODS: We examined the association between family history of cancer, AJ heritage, and incident pancreatic cancer in 49 410 male participants of the prospective Health Professionals Follow-up Study. Hazard ratios (HRs) were estimated using multivariable-adjusted Cox proportional hazards models...
March 14, 2019: British Journal of Cancer
Muhammad Kamil, Yoshinari Shinsato, Nayuta Higa, Takuro Hirano, Masashi Idogawa, Tomoko Takajo, Kentaro Minami, Michiko Shimokawa, Masatatsu Yamamoto, Kohichi Kawahara, Hajime Yonezawa, Hirofumi Hirano, Tatsuhiko Furukawa, Koji Yoshimoto, Kazunori Arita
BACKGROUND: Glioblastoma multiforme (GBM), the most common brain malignancy in adults, is generally aggressive and incurable, even with multiple treatment modalities and agents. Filamins (FLNs) are a group of actin-binding proteins that regulate the actin cytoskeleton in cells. However, the role of FLNs in malignancies-particularly in GBM-is unclear. METHODS: The relation between FLNC expression and overall survival in GBM was evaluated by the Kaplan-Meier analysis using GBM patients from the Kagoshima University Hospital (n = 90) and data from the Cancer Genome Atlas (TCGA) (n = 153)...
March 14, 2019: British Journal of Cancer
T Goranova, D Ennis, A M Piskorz, G Macintyre, L A Lewsley, J Stobo, C Wilson, D Kay, R M Glasspool, M Lockley, E Brockbank, A Montes, A Walther, S Sundar, R Edmondson, G D Hall, A Clamp, C Gourley, M Hall, C Fotopoulou, H Gabra, S Freeman, L Moore, M Jimenez-Linan, J Paul, J D Brenton, I A McNeish
This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License.
March 13, 2019: British Journal of Cancer
Marieke Erica Ijsselsteijn, Florent Petitprez, Laetitia Lacroix, Dina Ruano, Ruud van der Breggen, Catherine Julie, Hans Morreau, Catherine Sautès-Fridman, Wolf Herman Fridman, Noel Filipe da Cunha Carvalho de Miranda
In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited this paradox by characterising HLA class I expression in two independent cohorts of CRC. We determined that loss of HLA class I expression occurred in the majority (73-78%) of MMR-d cases...
March 13, 2019: British Journal of Cancer
Francesco Iachetta, Candida Bonelli, Alessandra Romagnani, Raffaella Zamponi, Lorenzo Tofani, Enrico Farnetti, Davide Nicoli, Angela Damato, Maria Banzi, Bruno Casali, Carmine Pinto
BACKGROUND: Deleterious polymorphisms in the gene encoding DPD (DPYD) may result in severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the standard dose of fluorouracil is used. The best panel of single-nucleotide polymorphism (SNPs) of DPYD is not well defined. METHODS: In 2011, we began screening DPYD*2A in patients candidate for fluoropyrimidine-based chemotherapy. We planned a case-control study with all cases of DPYD*2A wild type who developed toxicity ≥G3 and with a cohort of patients who did not present severe toxicities...
March 12, 2019: British Journal of Cancer
Deependra Singh, Joonas Miettinen, Stephen Duffy, Nea Malila, Janne Pitkäniemi, Ahti Anttila
The authors report that the labels indicating the symptom types and no symptom lines in the original version of Figure 2 were missing. The correct version of Figure 2 with the labels included is provided below.
March 6, 2019: British Journal of Cancer
Martina Mijuskovic, Edward J Saunders, Daniel A Leongamornlert, Sarah Wakerell, Ian Whitmore, Tokhir Dadaev, Clara Cieza-Borrella, Koveela Govindasami, Mark N Brook, Christopher A Haiman, David V Conti, Rosalind A Eeles, Zsofia Kote-Jarai
This article was originally published under the standard License to Publish, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.
March 6, 2019: British Journal of Cancer
Geraldine Perkins, Magali Svrcek, Cecile Bouchet-Doumenq, Thibault Voron, Orianne Colussi, Clotilde Debove, Fatiha Merabtene, Sylvie Dumont, Alain Sauvanet, Pascal Hammel, Jerome Cros, Thierry André, Jean-Baptiste Bachet, Armelle Bardier, Richard Douard, Tchao Meatchi, Frederique Peschaud, Jean-Francois Emile, Isabelle Cojean-Zelek, Pierre Laurent-Puig, Julien Taieb
BACKGROUND: Ampullary adenocarcinoma (AA) originates from either intestinal (INT) or pancreaticobiliary (PB) epithelium. Different prognostic factors of recurrence have been identified in previous studies. METHODS: In 91 AA patients of the AGEO retrospective multicentre cohort, we evaluated the centrally reviewed morphological classification, panel markers of Ang et al. including CK7, CK20, MUC1, MUC2 and CDX2, the 50-gene panel mutational analysis, and the clinicopathological AGEO prognostic score...
March 6, 2019: British Journal of Cancer
Zachary Klaassen, Christopher J D Wallis, Hanan Goldberg, Thenappan Chandrasekar, Rashid K Sayyid, Stephen B Williams, Kelvin A Moses, Martha K Terris, Robert K Nam, David Urbach, Peter C Austin, Paul Kurdyak, Girish S Kulkarni
BACKGROUND: Among patients with cancer, prior research suggests that patients with mental illness may have reduced survival. The objective was to assess the impact of psychiatric utilisation (PU) prior to cancer diagnosis on survival outcomes. METHODS: All residents of Ontario diagnosed with one of the top 10 malignancies (1997-2014) were included. The primary exposure was psychiatric utilisation gradient (PUG) score in 5 years prior to cancer: 0: none, 1: outpatient, 2: emergency department, 3: hospital admission...
March 6, 2019: British Journal of Cancer
Naohiro Tomita, Katsuyuki Kunieda, Atsuyuki Maeda, Chikuma Hamada, Takeharu Yamanaka, Toshihiko Sato, Kazuhiro Yoshida, Narikazu Boku, Riichiro Nezu, Shigeki Yamaguchi, Hideyuki Mishima, Sotaro Sadahiro, Kei Muro, Megumi Ishiguro, Junichi Sakamoto, Shigetoyo Saji, Yoshihiko Maehara
BACKGROUND: Up to 6-months oxaliplatin-containing regimen is now widely accepted as a standard adjuvant chemotherapy for stage III colorectal cancer (CRC). However, oral fluoropyrimidine monotherapy is used for some part of patients, especially in Asian countries including Japan, and its optimal duration is yet to be fully investigated. METHODS: A total of 1306 patients with curatively-resected stage III CRC were randomly assigned to receive capecitabine (2500 mg/m2 /day) for 14 out of 21 days for 6 (n = 654) or 12 (n = 650) months...
March 5, 2019: British Journal of Cancer
Can Liu, Hua He, Xiaobing Li, Maureen A Su, Yanguang Cao
Since the publication of this paper, the authors noticed that the funding information for Maureen A. Su was not included. Therefore the authors would like to add the following information to the Acknowledgements section.
March 4, 2019: British Journal of Cancer
Daniel G Piqué, Cristina Montagna, John M Greally, Jessica C Mar
BACKGROUND: Oncogenes promote the development of therapeutic targets against subsets of cancers. Only several hundred oncogenes have been identified, primarily via mutation-based approaches, in the human genome. Transcriptional overexpression is a less-explored mechanism through which oncogenes can arise. METHODS: Here, a new statistical approach, termed oncomix, which captures transcriptional heterogeneity in tumour and adjacent normal (i.e., tumour-free) mRNA expression profiles, was developed to identify oncogene candidates that were overexpressed in a subset of breast tumours...
March 1, 2019: British Journal of Cancer
Tarek M A Abdel-Fatah, Reuben J Broom, Jun Lu, Paul M Moseley, Baiqu Huang, Lili Li, Suling Liu, Longxin Chen, Runlin Z Ma, Wenming Cao, Xiaojia Wang, Yan Li, Jo K Perry, Mohammed Aleskandarany, Christopher C Nolan, Emad A Rakha, Peter E Lobie, Stephen Y T Chan, Ian O Ellis, Le-Ann Hwang, David P Lane, Andrew R Green, Dong-Xu Liu
BACKGROUND: SHON nuclear expression (SHON-Nuc+ ) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα+ breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT). METHODS: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα- early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamoxifen treatment...
February 28, 2019: British Journal of Cancer
Grayson M Donley, Wayne T Liu, Ruth M Pfeiffer, Emily C McDonald, Kamau O Peters, Margaret A Tucker, Elizabeth K Cahoon
BACKGROUND: Although the photosensitising effects of oestrogens may increase the impact of ultraviolet radiation (UVR) on melanoma risk, few prospective studies have comprehensively assessed the association between oestrogen-related factors and melanoma. METHODS: We examined the associations between reproductive factors, exogenous oestrogen use and first primary invasive melanoma among 167 503 non-Hispanic white, postmenopausal women in the NIH-AARP Diet and Health Study...
February 28, 2019: British Journal of Cancer
Lorenzo Dutto, Amar Ahmad, Katerina Urbanova, Christian Wagner, Andreas Schuette, Mustafa Addali, John D Kelly, Ashwin Sridhar, Senthil Nathan, Timothy P Briggs, Joern H Witt, Gregory L Shaw
Since the publication of this paper, the authors noticed that Amar Ahmad was not credited as contributing equally to the paper. He should be considered as a joint first author with Lorenzo Dutto. In addition, the author Ashwin Sridhar was incorrectly listed as Ashwin Shridhar, and the author Gregory L. Shaw was incorrectly listed as Gregory Shaw. The correct names are listed above.
February 27, 2019: British Journal of Cancer
Moritz J Strowitzki, Praveen Radhakrishnan, Sandra Pavicevic, Jana Scheer, Gwendolyn Kimmer, Alina S Ritter, Christopher Tuffs, Claudia Volz, Florian Vondran, Jonathan M Harnoss, Johannes Klose, Thomas Schmidt, Martin Schneider
BACKGROUND: Patients with borderline resectable colorectal liver metastases (CRLM) frequently receive neoadjuvant chemotherapy (NC) to reduce tumour burden, thus making surgical resection feasible. Even though NC can induce severe liver injury, most studies investigating tissue-based prognostic markers focus on tumour tissue. Here, we assessed the prognostic significance of pyruvate-dehydrogenase-kinase isoenzyme 4 (PDK4) within liver tissue of patients undergoing surgical resection due to CRLM...
February 27, 2019: British Journal of Cancer
Elin Hadler-Olsen, Anna Maria Wirsing
BACKGROUND: Various immune cells have been suggested as prognostic markers for cancer patients. In this article, we present a systematic review and meta-analysis of studies assessing the prognostic value of tissue-infiltrating immune cells in oral cancer and discuss the reporting quality of these studies. METHODS: We performed a systematic literature search and included studies using immunohistochemistry and survival analysis to assess the prognostic value of tumour-infiltrating T cells, B cells, macrophages, dendritic cells, mast cells and natural killer cells in oral cancer...
February 27, 2019: British Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"